Global CAR-T Cellular Immunotherapy Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CAR-T Cellular Immunotherapy Market Insights, Forecast to 2034
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.
Market Analysis and InsightsGlobal CAR-T Cellular Immunotherapy Market
Global CAR-T Cellular Immunotherapy market is expected to reach to US$ 682 million in 2024, with a positive growth of %, compared with US$ 632 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, CAR-T Cellular Immunotherapy industry is evaluated to reach US$ 913.9 million in 2029. The CAGR will be 5.0% during 2024 to 2029.
Globally, CAR-T Cellular Immunotherapy key companies include Fosun Kite Biotechnology, Gilead Sciences, Novartis and Bristol-Myers Squibb, etc. Fosun Kite Biotechnology, Gilead Sciences, Novartis are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of CAR-T Cellular Immunotherapy were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole CAR-T Cellular Immunotherapy market and estimated to attract more attentions from industry insiders and investors.
CAR-T Cellular Immunotherapy can be divided into Allogeneic and Autologous, etc. Allogeneic is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
CAR-T Cellular Immunotherapy is widely used in various fields, such as Hospital, Pharmacy and Other,, etc. Hospital provides greatest supports to the CAR-T Cellular Immunotherapy industry development. In 2022, global % revenue of CAR-T Cellular Immunotherapy went into Hospital filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global CAR-T Cellular Immunotherapy market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global CAR-T Cellular Immunotherapy market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Fosun Kite Biotechnology
Gilead Sciences
Novartis
Bristol-Myers Squibb
Segment by Type
Allogeneic
Autologous
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, CAR-T Cellular Immunotherapy introduction, etc. CAR-T Cellular Immunotherapy Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of CAR-T Cellular Immunotherapy
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal CAR-T Cellular Immunotherapy Market
Global CAR-T Cellular Immunotherapy market is expected to reach to US$ 682 million in 2024, with a positive growth of %, compared with US$ 632 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, CAR-T Cellular Immunotherapy industry is evaluated to reach US$ 913.9 million in 2029. The CAGR will be 5.0% during 2024 to 2029.
Globally, CAR-T Cellular Immunotherapy key companies include Fosun Kite Biotechnology, Gilead Sciences, Novartis and Bristol-Myers Squibb, etc. Fosun Kite Biotechnology, Gilead Sciences, Novartis are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of CAR-T Cellular Immunotherapy were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole CAR-T Cellular Immunotherapy market and estimated to attract more attentions from industry insiders and investors.
CAR-T Cellular Immunotherapy can be divided into Allogeneic and Autologous, etc. Allogeneic is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
CAR-T Cellular Immunotherapy is widely used in various fields, such as Hospital, Pharmacy and Other,, etc. Hospital provides greatest supports to the CAR-T Cellular Immunotherapy industry development. In 2022, global % revenue of CAR-T Cellular Immunotherapy went into Hospital filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global CAR-T Cellular Immunotherapy market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global CAR-T Cellular Immunotherapy market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Fosun Kite Biotechnology
Gilead Sciences
Novartis
Bristol-Myers Squibb
Segment by Type
Allogeneic
Autologous
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, CAR-T Cellular Immunotherapy introduction, etc. CAR-T Cellular Immunotherapy Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of CAR-T Cellular Immunotherapy
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices